Skip to main content
CivicGate

← Organizations

Todd Strategy Group

lobbying firm

Todd Strategy Group's federal footprint as a lobbying firm — reported lobbying it billed or handled on behalf of the clients it represents (this is the firm's reported revenue for that work, not its own spending). Figures are as reported to the U.S. Senate (LDA).

Lobbying from Senate LDA

Reported lobbying billed / handled $48,380,000
Firm activeFY2022–FY2026

Reported country: 🇺🇸 United States

Lobbying over time

Reported lobbying for Todd Strategy Group per filing year
FYLobbying billed / handled (as firm)
2022$8,700,000
2023$10,560,000
2024$13,280,000
2025$15,110,000
2026$730,000

Reported lobbying revenue for the clients Todd Strategy Group represents — not the firm's own spending.

Clients represented

  • Medical Countermeasures Coalition $1,480,000 · 10 filings
  • Alexion Pharmaceuticals, INC. $1,400,000 · 18 filings
  • Amgen INC. $1,320,000 · 18 filings
  • Novartis, INC. $1,290,000 · 19 filings
  • Genentech, INC. $1,030,000 · 17 filings
  • Pharmaceutical Research And Manufacturers Of America $1,020,000 · 17 filings
  • Gilead Sciences, INC. $970,000 · 17 filings
  • Siemens Healthineers $960,000 · 16 filings
  • Alnylam Pharmaceuticals, INC. $940,000 · 17 filings
  • Mckesson Corporation $900,000 · 18 filings

Clients Todd Strategy Group filed lobbying for, by reported amount billed/handled.

Issues

Issue area Worked
Health Issues 575
Medicare/Medicaid 456
Pharmacy 125
Budget/Appropriations 68
Copyright/Patent/Trademark 46
Taxation/Internal Revenue Code 39
Education 28
Tobacco 17
Banking 16
Telecommunications 16
Government Issues 14
Financial Institutions/Investments/Securities 13
Advertising 12
Communications/Broadcasting/Radio/TV 12
Economics/Economic Development 10
Labor Issues/Antitrust/Workplace 10
Science/Technology 10
Insurance 8
Medical/Disease Research/Clinical Labs 8
Trade (domestic/foreign) 7
Gaming/Gambling/Casino 6
Tariff (miscellaneous tariff bills) 5
Veterans 5

Issue areas across Todd Strategy Group's filings, by activity count. Linked areas open the CivicGate issue page.

What they lobbied on

Reported activity from Senate LDA

  • FY2026 Medicare/Medicaid

    General discussions around Medicare/Medicaid. Implementation of IRA.

  • FY2026 Health Issues

    Policy to advance pharmaceutical research and development. 340B.

  • FY2026 Medicare/Medicaid

    Implementation of Inflation Reduction Act of 2022.

  • FY2026 Copyright/Patent/Trademark

    Intellectual property.

  • FY2026 Health Issues

    General education about Freenome.

  • FY2026 Medicare/Medicaid

    Medicare coverage and reimbursement for diagnostics.

  • FY2026 Health Issues

    Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.

  • FY2026 Medicare/Medicaid

    General education about Inflammatix. Medicare coverage and reimbursement for diagnostics.

Show 52 more activities
  • FY2026 Pharmacy

    General education about Personalis. Lab test regulatory and reimbursement reform.

  • FY2026 Medicare/Medicaid

    Medicare coverage and reimbursement for diagnostics.

  • FY2026 Health Issues

    Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.

    H.R. 1

  • FY2026 Copyright/Patent/Trademark

    IP and Bayh-Dole Act.

  • FY2026 Medicare/Medicaid

    Medicare Part D.

  • FY2026 Pharmacy

    Implementation of the Inflation Reduction Act. PSA screening bills. Health care transparency.

  • FY2026 Health Issues

    NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.

    H.R. 7148

  • FY2026 Medicare/Medicaid

    Alternative payment model bonuses and incentive payments and freezing the qualifying provider revenue thresholds. Interoperability and Prior Authorization Final Rule. Hospital Inpatient Prospective Payment Systems. CMMI Reforms. Medicare Access and CHIP Reauthorization Act (MACRA). Accountable Care Organizations (ACOs) and Alternative Payment Models (APMs) in Medicare. Indirect practice expense. Medicare physician payment issues. MIPS quality and cost measures.

  • FY2026 Pharmacy

    Drug shortages.

  • FY2026 Health Issues

    HIPAA Coordinated Care Rulemaking.

  • FY2026 Health Issues

    Issues related to healthcare data privacy, cybersecurity, and artificial intelligence.

  • FY2026 Medicare/Medicaid

    General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.

  • FY2026 Medicare/Medicaid

    General discussions around Medicare/Medicaid. Implementation of IRA.

  • FY2026 Copyright/Patent/Trademark

    Copyright issues. Intellectual property protection.

  • FY2026 Health Issues

    General issues related to rare disease and orphan drugs.

  • FY2026 Health Issues

    Health insurance accessibility. Artificial Intelligence in health care.

  • FY2026 Medicare/Medicaid

    Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.

  • FY2026 Pharmacy

    Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.

  • FY2025 Health Issues

    Organ procurement regulations. Increasing access to organ transplant.

  • FY2025 Taxation/Internal Revenue Code

    Tax policy related to qualified business investment tax credit.

  • FY2025 Health Issues

    Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.

  • FY2025 Medicare/Medicaid

    General Medicare/Medicaid Issues. Safe STEP Act. 340B Issues.

  • FY2025 Education

    S.2296 - National Defense Authorization Act for Fiscal Year 2026.

    S. 2296

  • FY2025 Health Issues

    Policy to advance pharmaceutical research and development. 340B.

  • FY2025 Medicare/Medicaid

    Implementation of Inflation Reduction Act of 2022.

  • FY2025 Copyright/Patent/Trademark

    Intellectual property.

  • FY2025 Medicare/Medicaid

    General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.

  • FY2025 Telecommunications

    Spectrum. General telecommunications issues.

  • FY2025 Medicare/Medicaid

    Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.

  • FY2025 Health Issues

    Prescription Drug Pricing Policy. Supply Chain Issues.

  • FY2025 Taxation/Internal Revenue Code

    Prescription drug pricing policy.

  • FY2025 Medicare/Medicaid

    Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.

  • FY2025 Health Issues

    Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.

  • FY2025 Education

    General education issues. H.R.1383 - Secure Rural Schools Reauthorization Act of 2025.

    H.R. 1383

  • FY2025 Health Issues

    Rare Disease Issues.

  • FY2025 Medicare/Medicaid

    General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.

  • FY2025 Pharmacy

    Prescription drug pricing. Prostate cancer screening. Women's health.

  • FY2025 Health Issues

    Prescription drug pricing. Prostate cancer screening. Women's health.

  • FY2025 Medicare/Medicaid

    General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.

  • FY2025 Pharmacy

    Drug product quality assurance.

  • FY2025 Health Issues

    Biosecurity Issues.

  • FY2025 Economics/Economic Development

    General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.

  • FY2025 Taxation/Internal Revenue Code

    General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.

  • FY2025 Pharmacy

    PBM Policy Reform. Prior authorization. Utilization management.

  • FY2025 Tobacco

    Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.

  • FY2025 Budget/Appropriations

    Discussions concerning the FY 2024 appropriations bills; provisions related to FDA regulation of tobacco.

  • FY2025 Government Issues

    Discussions concerning federal funding related to the Centers for Disease Control and Prevention.

  • FY2025 Medicare/Medicaid

    340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

    S. 864

  • FY2025 Health Issues

    General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

    H.R. 1672 H.R. 946

  • FY2025 Medicare/Medicaid

    340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

    S. 864

  • FY2025 Health Issues

    General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.

    H.R. 1672 H.R. 946

  • FY2025 Health Issues

    Biosecurity Issues.

The specific issues and bills Todd Strategy Group reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.